The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)
Open accessAbstract
Purpose: The CROSS trial established neoadjuvant chemoradiotherapy (nCRT) for patients with resectable esophageal adenocarcinoma (rEAC). In the PERFECT trial, we investigated the feasibility and efficacy of nCRT combined with programmed-death ligand-1 (PD-L1) inhibition for rEAC. Patients and Methods: Patients with rEAC received nCRT according to the CROSS regimen combined with five cycles of atezolizumab (1,200 mg). The primary endpoint was the feasibility of administering five cycles of atezolizumab in ≥75% patients. A propensity score–matched nCRT cohort was used to compare pathologic response, overall survival, and progression-free survival. Exploratory biomarker analysis was performed on repeated tumor biopsies. Results: We enrolled 40 patients of whom 85% received all cycles of atezolizumab. Immune-related adverse events of any grade were observed in 6 patients. In total, 83% proceeded to surgery. Reasons for not undergoing surgery were progression (n = 4), patient choice (n = 2), and death (n = 1). The pathologic complete response rate was 25% (10/40). No statistically significant difference in response or survival was found between the PERFECT and the nCRT cohort. Baseline expression of an established IFNγ signature was higher in responders compared with nonresponders (P = 0.043). On-treatment nonresponders showed either a high number of cytotoxic lymphocytes (CTL) with a transcriptional signature consistent with expression of immune checkpoints, or a low number of CTLs. Conclusions: Combining nCRT with atezolizumab is feasible in patients with rEAC. On the basis of our exploratory biomarker study, future studies are necessary to elucidate the potential of neoadjuvant immunotherapy in patient subgroups. See related commentary by Catenacci, p. 3269
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Dindo, D., Demartines, N., & Clavien, P.-A. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000133083.54934.ae · Cited by 31,378
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
van Hagen, P., Hulshof, M. C. C. M., van Lanschot, J. J. B., Steyerberg, E. W., Henegouwen, M. I. V. B., Wijnhoven, B. P. L., Richel, D. J., Nieuwenhuijzen, G. A. P., Hospers, G. A. P., Bonenkamp, J. J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112088 · Cited by 5,521
Self-citationIFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
Becht, E., Giraldo, N. A., Lacroix, L., Buttard, B., Elarouci, N., Petitprez, F., Selves, J., Laurent-Puig, P., Sautès-Fridman, C., Fridman, W. H., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1070-5 · Cited by 3,685
Al-Batran, S.-E., Homann, N., Pauligk, C., Goetze, T. O., Meiler, J., Kasper, S., Kopp, H.-G., Mayer, F., Haag, G. M., Luley, K., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32557-1 · Cited by 2,648
Shapiro, J., van Lanschot, J. J. B., Hulshof, M. C. C. M., van Hagen, P., van Berge Henegouwen, M. I., Wijnhoven, B. P. L., van Laarhoven, H. W. M., Nieuwenhuijzen, G. A. P., Hospers, G. A. P., Bonenkamp, J. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00040-6 · Cited by 2,565
Self-citationThe evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Kang, Y.-K., Boku, N., Satoh, T., Ryu, M.-H., Chao, Y., Kato, K., Chung, H. C., Chen, J.-S., Muro, K., Kang, W. K., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31827-5 · Cited by 2,252
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053
Cited by
Liu, J., Yang, Y., Liu, Z., Fu, X., Cai, X., Li, H., Zhu, L., Shen, Y., Zhang, H., Sun, Y., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004291 · Cited by 282
Nie, R., Chen, F., Provencio, M., Wang, Y., van den Ende, T., van Laarhoven, H. W. M., Yuan, S., Pless, M., Hayoz, S., Zhou, Z., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.03.010 · Cited by 25
Self-citation
Metadata
- Authors
- van den Ende, T., de Clercq, N. C., van Berge Henegouwen, M. I., Gisbertz, S. S., Geijsen, E. D., Verhoeven, R. H. A., Meijer, S. L., Schokker, S., Dings, M. P. G., Bergman, J. J. G. H. M., Haj Mohammad, N., Ruurda, J. P., van Hillegersberg, R., Mook, S., Nieuwdorp, M., de Gruijl, T. D., Soeratram, T. T. D., Ylstra, B., van Grieken, N. C. T., Bijlsma, M. F., Hulshof, M. C. C. M., & van Laarhoven, H. W. M.
- Venue
- Clinical Cancer Research
- Published
- 2021-01-27
- Volume
- 27
- Issue
- 12
- Pages
- 3351-3359
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W3123367719
- Cited by
- 275
- References
- 29
- FWCI
- 44.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT). https://app.cochat.ai/papers/10.1158/1078-0432.ccr-20-4443
- The paper
- van den Ende, T., de Clercq, N. C., van Berge Henegouwen, M. I., Gisbertz, S. S., Geijsen, E. D., Verhoeven, R. H. A., Meijer, S. L., Schokker, S., Dings, M. P. G., Bergman, J. J. G. H. M., Haj Mohammad, N., Ruurda, J. P., van Hillegersberg, R., Mook, S., Nieuwdorp, M., de Gruijl, T. D., Soeratram, T. T. D., Ylstra, B., van Grieken, N. C. T., . . . van Laarhoven, H. W. M. (2021). Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT). Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-20-4443
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.